This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

Blame Keryx Executives, Not Short Sellers, for Dismal Drug Launch, Sinking Stock

07/07/15 - 07:43 AM EDT

Short sellers -- "manipulative" or otherwise -- are not responsible for Keryx's withering stock price. The problem is Auryxia, the company's kidney dialysis drug.

read more >

Other Articles by Adam

Free Reports

Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist

06/23/15 - 12:53 PM EDT

We've reached the stage of the biotech bull market where a sell-side analyst can value a company on sales of a cancer drug that doesn't even exist.

read more >
Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!

06/19/15 - 06:00 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Receptos Analyst Defends Company but Sounds Confused

06/18/15 - 08:52 AM EDT

I have some beefs with Leerink Partners biotech analyst Joe Schwartz and his research note in which he attempted to rebut my story about Receptos and the rampant takeout speculation.

read more >
Synergy Rises on Positive Results from Constipation Drug Study

06/17/15 - 11:58 AM EDT

Synergy Pharmaceuticals' experimental drug plecanatide significantly reduced chronic constipation compared to a placebo, achieving the primary goal of a late-stage study.

read more >
Receptos Insider Sale Defies Logic if Takeout Is Imminent

06/17/15 - 11:05 AM EDT

Lilly Ventures, the venture capital arm of the pharmaceutical giant with a seat on Receptos' board, just sold a good chunk of the company's stock.

read more >
Avalanche Fails Common-Sense Test, Kicked Out of Gene Therapy Credibility Club

06/16/15 - 06:53 AM EDT

I wanted to slam my forehead against the desk after the Avalanche CEO repeated for the 600th time, 'The key takeaway today is that it's a positive study.'

read more >
Agios Blood Cancer Drugs Are Fine -- It's the Analysis That's Causing Confusion

06/15/15 - 12:03 PM EDT

Agios shares are falling because investors thought the performance of its cancer drugs fell short, but only the method used to calculate response changed.

read more >
Bluebird Sickle Cell Gene Therapy Results Keep Getting Better

06/13/15 - 05:32 AM EDT

Six months after infusion with the Bluebird gene therapy known as LentiGlobin, almost half of the oxygen-carrying red blood cells in a single patient are normal and functioning.

read more >
Agios 'Cancer Metabolism' Drugs Induce Prolonged Responses in Blood Cancer Patients

06/12/15 - 05:55 AM EDT

Updated results from two early-stage studies of Agios' AG-221 and AG-110 are being presented at a European medical meeting.

read more >
Advisory Panel Recommends Bluebird Delay Gene Therapy Clinical Trial

06/09/15 - 08:18 PM EDT

The company's CEO said that Bluebird's plans had not changed despite a government panel's recommendation to delay the start of the trial until more data is gathered.

read more >
Page 2 of 337
Top Rated Stocks Top Rated Funds Top Rated ETFs